An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients

N/ANot Yet RecruitingNCT07142057

The First Affiliated Hospital of Guangzhou Medical University500 enrolled

Overview

To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

LUNG CANCER

Interventions

23-valent pneumococcal vaccineBIOLOGICAL

Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female patients \>=18 years of age; 2. Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received pneumococcal vaccine Exclusion Criteria: Patients having other factors that preventing researchers from enrollment them.

Outcomes

Primary Outcomes

The incidence of pneumonia at 12 months

During the 12-month follow-up period, the incidence of pulmonary infection in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.

Time frame: 12 months

Incidence of pneumonia

The proportion of lung cancer patients who developed pneumonia during the study period.

Time frame: 24 months

Secondary Outcomes

Survival rate

The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years).

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.